Document is current
Any future updates will be listed below
-
Authors
Khan, Muhammad S. https://orcid.org/0000-0002-6232-2633
Smego, Douglas
Li, Jing
Ishidoya, Yuki https://orcid.org/0000-0003-2825-8479
Offei, Emmanuel
Ruiz Castillo, Martha Sofia
Hirahara, Annie M.
Balmaceda, Pia
Hunter, Jennifer
Athavale, Anand
Revelo, Monica P.
Palatinus, Joseph A.
Selzman, Craig H.
Ranjan, Ravi
Hong, TingTing https://orcid.org/0000-0002-0243-5046
Dosdall, Derek J. https://orcid.org/0000-0001-5059-6824
Shaw, Robin M. https://orcid.org/0000-0001-7429-6092
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01HL171686, R01HL152691, R01HL159983, R01HL170196, R01HL128752, R21HL156039)
Nora Eccles Treadwell Foundation
American Heart Association (23CDA1057448)
- License Information
-
More Information
Article History
Received: 3 December 2023
Accepted: 25 February 2025
First Online: 27 March 2025
Competing interests
: R.M.S. and T.T.H. have founder’s equity in TikkunLev Therapeutics which is developing gene therapy solutions for non-ischemic cardiomyopathy. All other authors declare no competing interests.
